title: Medical management of alcohol dependence: clinical use and limitations of naltrexone treatment.
abstract: Historically, pharmacological and psychosocial treatments for alcohol dependence have demonstrated only modest effectiveness in reducing alcohol drinking. However, the recent US Food and Drug Administration approval of naltrexone for the treatment of alcohol dependence offers a new, safe and effective medication to reduce relapse following alcohol detoxification. This paper reviews the various psychosocial and pharmacological treatments currently available and the effectiveness of these treatments. This paper also reviews preclinical research which demonstrates the involvement of the opioid system in the reinforcing effects of alcohol. This research led to clinical trials on the use of the opioid antagonist, naltrexone, to reduce alcohol's pleasurable effects and enhance the effectiveness of psychosocial therapy. In two randomized clinical trials, naltrexone treatment reduced rates of alcohol relapse, number of drinking days and alcohol craving. The clinical efficacy of all pharmacological treatments for substance abuse are limited by compliance with taking the medication. Also, pharmacological treatment does not address the psychosocial complications which often result from chronic alcohol dependence. Therefore, the integration of medications such as naltrexone and psychosocial therapies may offer the best treatment. The further development and investigation of new pharmacological agents will enable matching of patient populations with specific treatments, offering more successful treatment outcomes.
authors.affiliation: Department of Psychiatry and Psychology, University of Pennsylvania, Philadelphia 19104, USA.
authors.forename: J R
authors.initials: JR
authors.lastname: Volpicelli
authors.forename: L A
authors.initials: LA
authors.lastname: Volpicelli
authors.forename: C P
authors.initials: CP
authors.lastname: O'Brien
mesh_terms: D000437:Alcoholism / Q000188:drug therapy* / Q000628:therapy; D003131:Combined Modality Therapy; D006801:Humans; D009271:Naltrexone / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D011613:Psychotherapy; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D013997:Time Factors
chemical_list: D009292:Narcotic Antagonists; D009271:Naltrexone